Biological E: News
Biological E is a long-standing Indian pharmaceutical company that was founded during the Swadeshi Movement in the country. The company was founded and led by Dr. D.K.V. Raju. It commenced operations in 1953 as a company making biological products such as liver extracts and anticoagulants. In 1962, the company transitioned to manufacturing DPT vaccines at a large scale so diseases could be prevented instead of treated. The wing responsible for this is called the Vaccines and Biologics division. When the Coronavirus pandemic gripped the world, this Hyderabad-based firm announced that it is developing a vaccine that could be 90 percent effective against the COVID-19 disease. The company’s COVID-19 vaccine called Corbevax entered the third stage of trials. Despite pending authorization, the Indian government paid Biological E a sum of Rs. 1,500 crore for 30 crore vaccine doses, enough to inoculate 15 Crore citizens. Additionally, the Corbevax jab is expected to be one of the cheapest ones on offer, costing just Rs.. 250 for both doses.
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon
India is set to begin the phase-2 trials of the world's first one-shot pneumococcal vaccine for adults soon.
35 lakh doses of J&J COVID-19 vaccine reach Kasauli lab
Around 35 lakh doses of the COVID-19 vaccine developed by United States pharma giant Johnson & Johnson have reportedly reached the apex vaccine testing laboratory in Kasauli, Himachal Pradesh.
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October
The one-dose COVID-19 vaccine developed by American pharma giant Johnson & Johnson and manufactured by the company's local partner, Hyderabad-based Biological E, is likely to be available in India by October, reported News18.
Phase 2/3 trials of Corbevax on 5-18 age group permitted
The Drugs Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct phase 2/3 clinical trials of its "Made in India" COVID-19 vaccine, Corbevax, on children aged between 5 and 18 years with certain conditions, sources said.
How Biological E's coronavirus vaccine could be a potential gamechanger
A made-in-India coronavirus vaccine being developed by the Hyderabad-based firm Biological E is expected to be up to 90% effective against COVID-19, an expert from a government advisory panel said.
India's neighbors train experts for clinical trials of COVID-19 vaccine
India's friendly neighboring nations trained over 100 experts to strengthen capacities in their countries for facilitating phase-3 clinical trials of the Indian COVID-19 vaccine, a senior official of the Department of Biotechnology said.
Modi to chair all-party meet to review COVID-19 situation Friday
Prime Minister Narendra Modi is set to chair an all-party meeting this Friday to review the COVID-19 situation in India, according to reports.